Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Subscribe To Our Newsletter & Stay Updated
